STERIS plc (STE)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $25.67B
Last updated: Nov 17, 2026 at 11:06 AM ET
STERIS plc (STE) Financials: Revenue, Profit and Cash Flow
STERIS reported revenue of $5.94B for the fiscal year ended Mar 31, 2026, up 8.7% from the year before. That year, net income was $785.10M with a net margin of 13.2%, operating cash flow was $1.34B and free cash flow was $972.40M. The quarter ended Sep 30, 2026 had revenue of $1.59B and net income of $214.10M.
Revenue and Margins
The operating margin was 18.6% in the fiscal year ended Mar 2026, the highest of the 10 years shown. Over the 9 years to Mar 2026, revenue grew from $2.61B, a compound annual rate of 9.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $5.94B | +8.7% | 44.2% | 18.6% | 13.2% |
| Mar 2025 | $5.46B | +6.2% | 44.0% | 15.9% | 11.3% |
| Mar 2024 | $5.14B | +13.3% | 43.2% | 16.3% | 7.4% |
| Mar 2023 | $4.54B | +7.4% | 43.7% | 17.4% | 2.3% |
| Mar 2022 | $4.22B | +35.9% | 44.6% | 11.3% | 5.8% |
| Mar 2021 | $3.11B | +2.5% | 43.2% | 17.6% | 12.8% |
| Mar 2020 | $3.03B | +8.9% | 43.6% | 17.7% | 13.5% |
| Mar 2019 | $2.78B | +6.2% | 42.2% | 14.8% | 11.0% |
| Mar 2018 | $2.62B | +0.3% | 41.7% | 15.3% | 11.1% |
| Mar 2017 | $2.61B | N/A | 39.3% | 8.7% | 4.2% |
Income Statement
In the fiscal year ended Mar 2026, net income rose 27.4% from the year before. In the quarter ended Sep 2026, net income rose 11.2% from the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.94B | $5.46B | $5.14B | $4.54B | $4.22B | $3.11B | $3.03B | $2.78B | $2.62B | $2.61B |
| Cost of revenue | $3.31B | $3.06B | $2.92B | $2.56B | $2.34B | $1.76B | $1.71B | $1.61B | $1.53B | $1.59B |
| Gross profit | $2.63B | $2.40B | $2.22B | $1.98B | $1.88B | $1.34B | $1.32B | $1.17B | $1.09B | $1.03B |
| Research and development | $112.90M | $107.60M | $103.70M | $98.48M | $86.66M | $66.33M | $65.55M | $63.04M | $60.78M | $59.40M |
| Operating income | $1.10B | $866.60M | $836.10M | $791.10M | $477.81M | $548.37M | $537.05M | $411.02M | $399.88M | $226.21M |
| Net income | $785.10M | $616.10M | $380.10M | $105.81M | $242.87M | $396.87M | $407.86M | $304.75M | $291.62M | $110.63M |
| EBITDA | $1.59B | $1.36B | $1.42B | $1.35B | $1.08B | $773.95M | $736.27M | $639.97M | $583.94M | $417.31M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.59B | $1.49B | $1.59B | $1.50B | $1.46B | $1.39B | $1.48B | $1.37B | $1.33B | $1.28B | $1.42B | $1.30B |
| Gross profit | $710.80M | $684.20M | $697.10M | $655.50M | $645.90M | $628.00M | $641.30M | $610.30M | $578.80M | $572.40M | $582.94M | $560.03M |
| Operating income | $294.30M | $285.80M | $316.80M | $273.20M | $265.80M | $246.00M | $216.10M | $245.30M | $219.70M | $185.50M | $220.32M | $226.47M |
| Net income | $214.10M | $201.00M | $220.30M | $194.30M | $192.50M | $178.00M | $146.10M | $173.30M | $151.20M | $145.50M | -$981.00K | $140.94M |
Balance Sheet
As of Mar 2026, total debt of $1.93B exceeded cash and equivalents by $1.49B.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $10.74B | $10.15B | $11.06B | $10.82B | $11.42B | $6.57B | $5.44B | $5.07B | $5.20B | $4.92B |
| Current assets | $2.39B | $2.00B | $2.87B | $2.01B | $1.88B | $1.21B | $1.22B | $1.05B | $989.66M | $1.02B |
| Cash and equivalents | $439.60M | $171.70M | $207.02M | $208.36M | $348.32M | $220.53M | $319.58M | $220.63M | $201.53M | $282.92M |
| Total liabilities | $3.54B | $3.53B | $4.75B | $4.73B | $4.88B | $2.68B | $2.02B | $1.89B | $1.98B | $2.11B |
| Short-term debt | $118.90M | $125.00M | $85.94M | $60.00M | $142.88M | $0 | $19.81M | $0 | $74.70M | $71.02M |
| Long-term debt | $1.81B | $1.92B | $3.12B | $3.02B | $2.95B | $1.65B | $1.15B | $1.18B | $1.32B | $1.48B |
| Shareholder equity | $7.18B | $6.60B | $6.30B | $6.08B | $6.53B | $3.88B | $3.41B | $3.18B | $3.21B | $2.81B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $10.71B | $10.74B | $10.74B | $10.59B | $10.41B | $10.40B | $10.15B | $10.01B | $10.24B | $10.11B | $11.06B | $11.44B |
| Total liabilities | $3.44B | $3.51B | $3.54B | $3.42B | $3.39B | $3.44B | $3.53B | $3.58B | $3.63B | $3.74B | $4.75B | $5.01B |
| Cash and equivalents | $531.10M | $482.30M | $439.60M | $423.70M | $319.20M | $279.70M | $171.70M | $155.18M | $172.19M | $198.33M | $207.02M | $195.59M |
| Shareholder equity | $7.26B | $7.21B | $7.18B | $7.15B | $7.01B | $6.96B | $6.60B | $6.42B | $6.59B | $6.35B | $6.30B | $6.42B |
Cash Flow
In the fiscal year ended Mar 2026, free cash flow was 72.6% of operating cash flow. Dividends and share repurchases together came to 49.3% of it.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.34B | $1.15B | $973.30M | $756.95M | $684.81M | $689.64M | $590.56M | $539.50M | $457.63M | $424.09M |
| Capital expenditures | $369.00M | $370.10M | $360.30M | $361.97M | $287.56M | $239.26M | $214.52M | $189.72M | $165.46M | $172.90M |
| Free cash flow | $972.40M | $778.00M | $613.00M | $394.98M | $397.25M | $450.38M | $376.04M | $349.79M | $292.18M | $251.19M |
| Dividends paid | $243.60M | $222.40M | $208.40M | $185.76M | $196.84M | $140.41M | $124.91M | $114.08M | $106.39M | $103.11M |
| Share repurchases | $235.50M | $211.30M | $11.80M | $308.56M | $55.78M | $14.65M | $51.24M | $81.49M | $65.48M | $97.51M |
| Investing cash flow | -$512.50M | $388.80M | -$887.40M | -$383.33M | -$666.56M | -$1.15B | -$319.74M | -$213.22M | -$203.83M | -$104.25M |
| Financing cash flow | -$568.20M | -$1.57B | -$85.20M | -$498.72M | $115.83M | $345.62M | -$163.15M | -$294.79M | -$356.18M | -$267.10M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $289.00M | $367.10M | $335.40M | $298.20M | $287.80M | $420.00M | $260.80M | $332.80M | $250.80M | $303.70M | $254.83M | $291.24M |
| Capital expenditures | $76.10M | $87.50M | $90.20M | $98.70M | $86.50M | $93.60M | $70.90M | $89.20M | $101.90M | $108.10M | $91.47M | $118.94M |
| Free cash flow | $212.90M | $279.60M | $245.20M | $199.50M | $201.30M | $326.40M | $189.90M | $243.60M | $148.90M | $195.60M | $163.36M | $172.31M |
Frequently Asked Questions About STE
What is STERIS's annual revenue?
STERIS reported revenue of $5.94B for the fiscal year ended Mar 31, 2026.
How fast is STERIS's revenue growing?
Revenue was up 8.7% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 9.4%.
Is STERIS profitable?
Yes. STERIS reported net income of $785.10M for the fiscal year ended Mar 31, 2026, with a net margin of 13.2%.
How much free cash flow does STE generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of $1.34B minus capital expenditures of $369.00M produced free cash flow of $972.40M.
How much debt does STERIS have?
The balance sheet dated Mar 31, 2026 reported long-term debt of $1.81B, short-term debt of $118.90M and cash and equivalents of $439.60M.
STE pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts